Ridsivir antidote expects to burst?Related A-share company stocks plunge

Ridsivir antidote expects to burst?Related A-share company stocks plunge
Sauna Night News (reporter Li Yunqi) adopts reports that Radexivir may be ineffective for New Coronary Pneumonia, and dividend Ridsivir related stocks are affected.In early trading on April 24, the listed company Bo Teng shares opened a daily limit.In addition, the stocks of Borui Pharmaceutical, Zhongda University, Jiuzhou Pharmaceutical, Yongtai Technology, and Kelun Pharmaceutical also declined.On April 23, U.S. time, foreign media cited the World Health Organization’s Unexpected Document Index report that Gilead’s potential anti-new coronavirus drug ridxivir failed in the first randomized clinical trial.Gilead, a Red West Sawson manufacturer, plunged 4 times during the session.43%.On the same day, Gilead Sciences issued a public statement saying that the World Health Organization prematurely released information about China’s first clinical study, which is that researchers can permit the release of the results, and the information has been deleted.Gilead believes that the article published by the World Health Organization contains an inappropriate description of the study, “Because of the low enrollment rate, the study was terminated early, so its data is not sufficient to support statistically significant performance.””[Gilead: China ‘s critical clinical research data is not enough to support statistically significant statistics], on the afternoon of April 24, Gilead Science issued a Chinese version statement on the official WeChat platform, which was prematurely published on the World Health Organization website.Information from the first clinical study in China, which evaluated the use of the antiviral drug Ridesivir in severely ill patients with the new coronavirus pneumonia.Gilead proposed that the above study was terminated early due to the low enrollment rate, “its data are not sufficient to support a statistically meaningful response.”For its part, the results of this study are non-diabetic, although the trend of the data suggests potential benefits of redoxivir, especially among patients who are treated early.We learned that the existing data has been submitted for peer-reviewed release, and we will see more detailed information on this research later.”At the same time, Gilead Science once again announced the expected release time of the redoxivir research data, saying that it is expected to release the results of an open-label study on redoxivir for severe patients with new coronavirus pneumonia at the end of this month.Gilead said that this is a randomized clinical trial and all patients have been enrolled. The study will compare the treatment results and safety of 5 days or 10 days after the use of reducivir. “We expect to obtain the alignment at the end of May.Data from an open-label study of patients with psychiatric disorders, this study will compare the results of patients receiving Radecivir for 5 days, 10 days, and receiving standard treatment.Gilead expects to also receive data from the National Institute of Allergy and Infectious Diseases (NIAID) in a double-blind, placebo-controlled study of ridacive in patients of varying severity at the end of May.On April 10, the Air Force announced the results of its first clinical trial. The sample evaluated data from 53 patients from the United States, Europe, Canada, and Japan that indicated a median of 18 days after the first use of ridxivirApproximately in advance, 68% of patients receiving Radecivir improved oxygen support levels.The overall mortality rate for this mortality rate is 13%, and the mortality rate for the subgroup of patients with invasive ventilation is 18%, which is higher than the mortality rate of 5% for patients with noninvasive ventilation support.According to media reports, a draft document issued by the World Health Organization “accidentally” showed that in a clinical trial in China, 237 patients participated in the trial. The results of the trial showed that the use of the drug was not related to the patient’s condition improving or worsening.The mortality rate of patients using the drug was 13.9%, compared with 12 deaths in patients receiving standard treatment.8%.The earliest is that in early February, China launched some preliminary studies on severe and moderately ill patients.Since then, the five additional Randavivir trials have been launched around the world.However, in addition to the above-mentioned draft documents issued by the World Health Organization “accidentally”, the clinical trials conducted by Reducive in China have not published results.On February 25 of the Air Force, the State Intellectual Property Office publicly stated that the results of the clinical trials of ridxivir will be announced on April 27.[Reed Westwell-related stocks plummeted to the bottom of Botten shares]On April 24th, a long-term listed company that had issued news related to Reed Westweg Lied fell sharply.Among them, Bo Teng shares fell in early trading, Yongtai Technology’s largest decline was more than 9%, and Borui Pharmaceutical’s largest decline was more than 5%.Looking back at the beginning of February, through Gilead’s announcement of the clinical research development of Ridesivir in the world, some domestic Gilead partners have also made statements related to Gilead or Ridesivir.Daily limit.From the opening of the market on February 3 to February 10, the listed company Bo Teng shares had a daily limit of 6 consecutive trading days, which has been closed from 15 on January 23.76 yuan / share rose to 27 on February 10 closing.93 yuan / share.At that time, Bo Teng shares issued an announcement on the evening of February 4th that Gilead was the company ‘s core customer. The company began to provide customized R & D and production services for Gilead Scientific ‘s antiviral drug Ridesivir in 2015, and more than 2016The senior middleman who delivered the clinical requirements at the second time, “ultimately, according to the company’s business information, the above matters will not have a significant impact on the company’s 2020 performance.”On February 11, Borui Pharmaceuticals announced that it has successfully developed the synthesizing process technology and formulation technology of rudexivir API, and has already mass-produced rusixivir API.After the news was released, Borui Pharmaceutical’s stocks grew rapidly, reaching a 20% surge on February 12, and 19 on February 13 and 14, respectively.99%, 10.17%.The decision of the Shanghai Stock Exchange on March 1 showed that the “mass production” mentioned in the announcement of Borui Pharmaceuticals is actually a substitute for pilot production of small and medium-sized test and pilot test for drug research and development. On March 2, Borui Pharmaceuticals is expected to fall, falling -14.67%.Opening on April 24, Borui Pharmaceuticals declined and the largest intraday drop was more than 5%.Yongtai Technology also suffered from Ridewell’s surge. The data shows that Yongtai Technology set five consecutive daily limits from February 3 to 6, and the total market value soared by nearly 50 billion.At that time, Yongtai Technology stated on the investor question and answer platform that the company’s downstream customers include companies such as Gilead and Bayer.Recently, the company recognizes that Gilead’s research drug Ridesivir can be used to treat new coronavirus pneumonia. The company is actively approaching Gilead’s downstream customers and other downstream customers to seek possible cooperation opportunities.In addition, Jiuzhou Pharmaceutical, a listed company that provides pharmaceutical intermediate services to Gilead Sciences, saw its stocks rise sharply from February 3rd to 6th, during which there were three consecutive daily limits.In fact, at that time, Jiuzhou Pharmaceutical also reminded investors many times that it did not conduct substantial cooperation with Gilead on the new coronavirus pneumonia drug Ridesivir.On April 24, Yongtai Technology opened lower in early trading, with the largest intraday drop of more than 9.At 8%, the decline was expected to stop several times; Jiuzhou Pharmaceutical opened lower in early trading, reaching a maximum decline of more than 3%.Sauna, Ye.net editor Yun Caizhou proofread Wang Xin